2010
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor
Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor. Molecular Cancer Therapeutics 2010, 9: 706-717. PMID: 20197390, PMCID: PMC2837366, DOI: 10.1158/1535-7163.mct-09-0985.Peer-Reviewed Original ResearchMeSH Keywords3-Phosphoinositide-Dependent Protein KinasesAnimalsAntineoplastic AgentsFemaleHumansMiceMice, Inbred C57BLMice, NudeModels, BiologicalOncogene Protein v-aktProtein BindingProtein Interaction Domains and MotifsProtein Kinase InhibitorsProtein Serine-Threonine KinasesSulfonamidesThiadiazolesTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsAntitumor activityTumor xenograftsNon-small cell lung cancerMolecular pharmacologyCell lung cancerAdditive antitumor activityHuman tumor xenograftsPHT-427K-ras mutant tumorsVivo antitumor activityLung cancerSensitive tumorsPIK3CA mutationsBreast cancerImmunodeficient miceBlood chemistryMutant tumorsCombination studiesResistant cellsMinimal toxicityWeight lossTumorsCancerCancer cellsAkt inhibition
2001
Lung cancer in patients under age 40
Skarin A, Herbst R, Leong T, Bailey A, Sugarbaker D. Lung cancer in patients under age 40. Lung Cancer 2001, 32: 255-264. PMID: 11390007, DOI: 10.1016/s0169-5002(00)00233-6.Peer-Reviewed Original ResearchConceptsStage IV diseaseSmall cell carcinomaSquamous cell carcinomaCell carcinomaPerformance statusStage IIIBStage IIIAOlder patientsLung cancerYear survivalAge 40Stage I/IIDana-Farber Cancer InstituteGreater body weight lossWeight lossECOG performance statusPercent of patientsPoor performance statusDuration of symptomsSite of metastasisOverall patient survivalStage of diseaseBody weight lossAbsence of symptomsPercentage of women